



Title	Increased ACE2 and TMPRSS2 expression in ulcerative colitis
Author(s)	Hamamoto, Yuichiro; Kawamura, Michihiro; Uchida, Hiroki et al.
Citation	Pathology Research and Practice. 2024, 254, p. 155108
Version Type	AM
URL	https://hdl.handle.net/11094/98829
rights	© 2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Note	

The University of Osaka Institutional Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

The University of Osaka

Table 1. Patients' list with C-reactive protein (CRP) values and immunohistochemical results

Patient	Group	Age	CRP (mg/dL)	ACE2 score		TMPRSS2 score	
				proportion	intensity	proportion	intensity
1	UC post COVID-19 pandemic	28	0.25	1	1	3	3
2	UC post COVID-19 pandemic	45	0.02	1	2	3	3
3	UC post COVID-19 pandemic	56	0.04	1	2	3	3
4	UC post COVID-19 pandemic	65	0.34	2	1	3	3
5	UC post COVID-19 pandemic	41	0.06	1	3	3	3
6	UC post COVID-19 pandemic	63	0.3	1	1	3	3
7	UC post COVID-19 pandemic	30	0.09	1	1	3	3
8	UC post COVID-19 pandemic	39	0.1	1	1	3	3
9	UC post COVID-19 pandemic	68	0.11	1	3	3	3
10	UC post COVID-19 pandemic	76	0.7	1	3	3	3
11	UC post COVID-19 pandemic	61	0.43	2	2	3	3
12	UC post COVID-19 pandemic	54	0.05	1	3	3	3
13	UC post COVID-19 pandemic	50	6.89	2	2	3	3
14	UC post COVID-19 pandemic	69	0.05	1	3	3	3
15	UC post COVID-19 pandemic	46	0.91	0	0	3	3
16	Control post COVID-19 pandemic	79	NA	1	1	3	3
17	Control post COVID-19 pandemic	87	NA	1	1	3	3
18	Control post COVID-19 pandemic	83	NA	1	3	3	3
19	Control post COVID-19 pandemic	89	NA	1	3	3	3
20	Control post COVID-19 pandemic	94	NA	1	2	3	3

21	Control post COVID-19 pandemic	76	NA	1	2	3	3
22	Control post COVID-19 pandemic	88	NA	1	1	3	3
23	Control post COVID-19 pandemic	80	NA	1	2	3	3
24	Control post COVID-19 pandemic	41	NA	2	2	3	3
25	Control post COVID-19 pandemic	77	NA	1	2	3	3
26	Control post COVID-19 pandemic	71	NA	0	0	3	3
27	Control post COVID-19 pandemic	75	NA	1	3	3	3
28	Control post COVID-19 pandemic	80	NA	1	2	3	3
29	Control post COVID-19 pandemic	85	NA	1	3	3	2
30	Control post COVID-19 pandemic	89	NA	1	2	3	3
31	UC pre COVID-19 pandemic	62	0.07	1	3	3	3
32	UC pre COVID-19 pandemic	67	NA	1	3	3	3
33	UC pre COVID-19 pandemic	38	NA	1	2	3	3
34	UC pre COVID-19 pandemic	42	0.03	1	3	3	3
35	UC pre COVID-19 pandemic	43	0.16	1	1	3	3
36	UC pre COVID-19 pandemic	22	0.05	1	3	3	3
37	UC pre COVID-19 pandemic	55	0.23	2	2	3	3
38	UC pre COVID-19 pandemic	69	0.03	2	2	3	3
39	UC pre COVID-19 pandemic	72	0.49	0	0	3	3
40	UC pre COVID-19 pandemic	68	0.02	2	2	3	3
41	UC pre COVID-19 pandemic	35	0.97	1	2	3	3
42	UC pre COVID-19 pandemic	34	0.04	1	2	3	3
43	UC pre COVID-19 pandemic	61	0.11	2	3	3	3

44	UC pre COVID-19 pandemic	35	3.29	1	3	3	3
45	UC pre COVID-19 pandemic	59	5.62	3	3	3	3
46	Control pre COVID-19 pandemic	78	NA	1	3	2	3
47	Control pre COVID-19 pandemic	91	NA	1	3	3	2
48	Control pre COVID-19 pandemic	77	NA	1	3	3	3
49	Control pre COVID-19 pandemic	77	NA	1	3	3	3
50	Control pre COVID-19 pandemic	83	NA	1	3	3	2
51	Control pre COVID-19 pandemic	75	NA	1	2	3	2
52	Control pre COVID-19 pandemic	61	NA	0	2	2	2
53	Control pre COVID-19 pandemic	76	NA	1	2	3	3
54	Control pre COVID-19 pandemic	60	NA	1	3	1	2
55	Control pre COVID-19 pandemic	71	NA	1	1	3	3
56	Control pre COVID-19 pandemic	61	NA	1	3	3	3
57	Control pre COVID-19 pandemic	83	NA	0	0	3	2
58	Control pre COVID-19 pandemic	71	NA	1	3	3	3
59	Control pre COVID-19 pandemic	71	NA	1	3	3	3
60	Control pre COVID-19 pandemic	76	NA	1	3	3	3

NA, not available; UC, ulcerative colitis

Table 2. Primary antibodies

Antibody	Clone	Dilution	Manufacturer	Control cells
ACE2	EPR4435(2)	1:200	abcam	renal tubular epithelium
TMPRSS2	EPR3862	1:100	abcam	renal tubular epithelium